Skip to content

节律制药

US · RYTM #1874 按市值排名 上市于 2017
86.17 -1.80 -2.05%
实时 - 追踪5344个代码 - 心跳于466秒前 · 2026-10-16 20:01

✦ 量化股权信号 计算方式说明

减持
  • 最近一期（2026/Q3）披露持股的机构数量减少了3家。
  • 机构持股总比例下降了0.3个百分点。

机构持股

机构持股比例
113.31% -0.26pp
机构数量
380 -3
数据截至
2026/Q3 较上一报告期

持股变动 vs 资金流向

方向分歧

机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流入——两者方向出现分歧。

机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。

持股人类型

Mutual Fund69.09%
Hedge Fund18.62%
VC/PE Fund16.22%
Public Company4.84%
Private Company2.38%
Sovereign Wealth Fund1.01%
Individual/Insider0.79%
Government Pension Fund0.56%
Family Office/Trust0.38%

主要股东 截至 2026-06-30

RA Capital Management, L.P. 9.68% · 6.67M 股
BlackRock 8.94% · 6.16M 股
Baker Bros. Advisors LP 8.14% · 5.60M 股
Vanguard Capital Management, LLC 5.01% · 3.45M 股
PRIMECAP Management Company 4.60% · 3.17M 股
Vanguard Portfolio Management, LLC 4.56% · 3.14M 股
Perceptive Advisors LLC 3.76% · 2.59M 股
State Street Global Advisors 3.74% · 2.57M 股
T. Rowe Price Group, Inc. 3.73% · 2.57M 股
J.P. Morgan Asset Management, Inc. 3.72% · 2.56M 股

条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。

内部人持股

共追踪50份申报 · 28次买入 · 22次卖出

姓名职务持股比例
David Meeker Chairperson & CEO 0.35%
Hunter Smith Chief Financial Officer 0.17%
Yann Mazabraud Executive VP & Head of International 0.08%
Pamela Cramer Chief Human Resources Officer 0.04%
Edward Mathers Former Lead Independent Director 0.03%
Joseph Shulman Chief Technology Officer 0.02%
Stuart Arbuckle Former Independent Director 0.02%
Jennifer Good Former Independent Director 0.02%
Lynn Tetrault Former Independent Director 0.02%
Christophe Jean Former Independent Director 0.02%

内部人交易 最近的 Form 4 申报记录

日期姓名职务类型股数价格
2026-09-13 David Meeker Chairperson & CEO Derivative Exercise and Sale -50,000 $6.05–105.19
2026-08-30 Hunter Smith Chief Financial Officer Automatic Disposition -5,587 $106.20
2026-08-30 Hunter Smith Chief Financial Officer Derivative Exercise and Sale -57,187 $25.79–106.20
2026-08-16 Manher Joshi Chief Medical Officer Other Derivative Acquisition +25,000 --
2026-08-16 Manher Joshi Chief Medical Officer Other Derivative Acquisition +50,000 $115.44
2026-08-12 Joseph Shulman Chief Technology Officer Automatic Disposition -3,055 $119.75
2026-08-12 Joseph Shulman Chief Technology Officer Derivative Exercise and Sale -2,024 $6.80–119.75
2026-08-12 Alastair Garfield Former VP & Head of Research Automatic Disposition -7,763 $116.11–119.17
2026-08-12 Jennifer Lee Executive VP & Head of North America Automatic Disposition -19,233 $117.38
2026-08-12 Jennifer Lee Executive VP & Head of North America Derivative Exercise and Sale -56,601 $6.80–117.38
2026-08-11 Yann Mazabraud Executive VP & Head of International Automatic Disposition -10,375 $117.47
2026-08-11 Yann Mazabraud Executive VP & Head of International Derivative Exercise and Sale -46,625 $6.80–117.47
2026-08-10 Pamela Cramer Chief Human Resources Officer Intent to Sell (Form 144) -11,406 $115.48
2026-08-09 Pamela Cramer Chief Human Resources Officer Intent to Sell (Form 144) -3,520 $115.63
2026-06-30 Alastair Garfield Former VP & Head of Research Derivative Exercise and Sale -2,150 $110.41
2026-06-30 Alastair Garfield Former VP & Head of Research Derivative Exercise and Retained +2,295 --
2026-06-23 Jennifer Good Former Independent Director Other Derivative Acquisition +2,324 --
2026-06-23 Jennifer Good Former Independent Director Other Derivative Acquisition +3,691 $107.55
2026-06-23 David W. McGirr Independent Director Other Derivative Acquisition +2,324 --
2026-06-23 David W. McGirr Independent Director Other Derivative Acquisition +3,691 $107.55

Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。

报价时间 2026-10-16 20:01:17 · 仅供参考，不构成投资建议，也未考虑您的具体情况。

节律制药 讨论区 0 条评论

发表评论